Singapore, March 21, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it received four awards at the 2024 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony, and that the company’s President of Global Biologics Development and Operations and Chief Technology Officer (CTO), Dr. Weichang Zhou, was honored with CTO of the Year 2023.
WuXi Biologics stood out in the following categories, achieving its highest number of awards since first receiving ABEA recognition in 2017:
- Best Contract Development and Manufacturing Organization Award
- Bioprocessing Excellence in Greater China Region
- Best Bioprocessing Supplier Award
- Best Aseptic Fill-Finish & Packaging CMO of the Year
Sponsored by IMAPAC, a leading consulting firm in the biopharmaceutical industry, the ABEA seeks to recognize the outstanding achievements of top leaders in biomanufacturing, biologistics and clinical trials, applauding extraordinary leaders and trend-setters of today and inspiring innovators of tomorrow.
WuXi Biologics provides end-to-end services for nearly 600 clients worldwide. With its innovative technologies, world-class quality systems, extensive global manufacturing network and proven success rates, the company enables clients to advance their biologics into the clinic and on to the market.
The company’s drug product GMP manufacturing services have been validated by major regulatory agencies, including the FDA, EMA and China NMPA, as well as by over 1,000 quality audits from global clients. An overall success rate of 99%+ has been achieved for more than 1,700 batches of drug products.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “The multiple awards WuXi Biologics received are a true testament to the value we have created for our clients and for the industry. With an unwavering commitment to excellence and quality, a strong leadership team and dedicated people, we will continue to enable our clients to accelerate breakthrough treatments to benefit patients worldwide.”
Dr. Weichang Zhou won CTO of the Year award for his remarkable leadership and achievements in pioneering technology innovations to expedite biologics development and manufacturing.
Dr. Zhou said, “I am honored to receive this award. It is exciting to be part of the advancement of more flexible, productive, and efficient approaches as our team at WuXi Biologics works to enhance technologies that help increase the global accessibility and affordability of biologic therapies. “
About IMAPAC
IMAPAC is a leading event management company specializing in the biopharmaceutical industry. With over 12 years of experience, IMAPAC has successfully organized more than 50 industry events, attracting over 15,000 participants from around the world. IMAPAC’s events are renowned for their high-quality content, prestigious speakers, and networking opportunities.
